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The natural polyisoprenylated benzophenone derivatives garcinol and isogarcinol are secondary plant
metabolites isolated from various Garcinia species including Garcinia indica. This review takes stock of the recent
chemical and biological research into these interesting natural compounds over the last five years. New
biological sources and chemical syntheses are discussed followed by new insights into the activity of garcinol
and isogarcinol against cancer, pathogenic bacteria, parasite infections and various inflammatory diseases.
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1. Introduction
Natural products and their semi-synthetic derivatives
occupy a salient position concerning activity and
percentage share of new investigational and eventu-
ally approved drugs for the clinic.[1] The traditional folk
medicine of East Asia (Traditional Chinese Medicine,
Kampo), South Asia (Ayurveda, Unani), the Middle-East
(traditional Greco-Arab and Islamic Medicine) and
other Asian regions, in particular, proved to be a
valuable source of drug discovery based on natural
products.[2,3] In India, for example, plants or plant
products from Boswellia, Curcuma, Plumbago, Law-
sonia, and Garcinia among others, whose manifold
activities were confirmed by modern laboratories
meanwhile, have been applied by traditional healers
until today.[4,5] Garcinia species produce the biolog-
ically active benzophenones/polycyclic polyprenylated
acylphloroglucinols (PPAPs) garcinol and isogarcinol
which have raised the interest of chemists and
molecular biologists alike (Figure 1).[6,7] Garcinol is
easily available in large amounts and high purity by
extraction of dried kokum plums (Garcinia indica)
followed by chromatographic purification and/or
crystallization.[6,8] Isogarcinol is easily prepared from
garcinol by treatment with diluted hydrochloric acid.[9]
The activity spectra of garcinol and isogarcinol include
anticancer, antibiotic, antioxidant and anti-inflamma-
tory effects.[10] Their modes of action are diverse and
include the inhibition of NF-κB and STAT as well as of
histone acetyl transferases (HATs).[11] Several reviews
and book chapters covered the extensive chemistry
and biological activities of garcinol and isogarcinol
over the last decade.[4,6,7,10,11] The present review
highlights the most recent proceedings in this field.
2. An Update on The Isolation, Analysis, and
Synthesis of Garcinol and Isogarcinol
Garcinol and isogarcinol were isolated from various
Garcinia species. High yields of garcinol can be
obtained from dried kokum (Garcinia indica) plums
while garcinol can be easily converted to isogarcinol
under acidic conditions.[6,8] High yields of garcinol (up
to 5 g from 500 g dried kokum plums) were achieved
Figure 1. Structures of the natural products garcinol and
isogarcinol.
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by extraction of chopped dried kokum plums with
methanol, evaporation of the solvent, redissolution of
the methanol extract in ethyl acetate, washing of the
latter with water, column chromatography of the
concentrated ethyl acetate extract (silica gel 60, ethyl
acetate/hexane 1:2) followed by crystallization of the
concentrated eluate from hexane to give yellow
needles.[6] Isogarcinol can be easily prepared by treat-
ment of garcinol with aqueous HCl in toluene at room
temperature.[6] Another suitable large scale isolation
method initially removed hydroxycitric acid from
Garcinia indica fruits by washing with water, followed
by methanol extraction of the fruits, adsorption of the
concentrated methanol extract on Celite and extrac-
tion of the methanol extract loaded Celite with hexane
followed by column chromatography of the hexane
extract.[8] Recently, garcinol and isogarcinol were
isolated from fruits of Garcinia multiflora, a medicinal
plant of South China known for its antioxidant
activity.[10,12] The authors obtained 500 mg garcinol
and 101 mg isogarcinol from 5.2 kg dried G. multiflora
fruits (powdered dried G. multiflora fruits were ex-
tracted with 95% ethanol and the ethanol extract was
extracted with petroleum ether followed by column
chromatography on silica gel and recrystallization to
obtain garcinol).[12] Garcinol was also detected in and
isolated from plants of the Garcinia species G. morella,
G. yunnanensis, G. xanthochymus and G.
travancorica.[13–16] In addition, garcinol and isogarcinol
were recently found in the stem bark of the Garcinia
species G. buchananii.[17] Isogarcinol was also isolated
from G. punctata and G. ovalifolia.[18,19]
Quantitative analyses of garcinol contents in bio-
logical material are usually carried out by LC/MS and
HPLC methods.[20–22] Recently, the garcinol contents of
Garcinia indica samples and of the commercially
available formulations Tryodashang Guggul and Slim-
merz capsules was determined by High Performance
Thin Layer Chromatography (HPTLC). It was shown
that the dried fruit rinds of Garcinia indica contained
2.5% garcinol while Tryodashang Guggul had 0.701%
and Slimmerz capsules 0.760% garcinol.[23] With
aqueous two-phase systems (ATPS) containing ethanol
and ammonium sulfate garcinol and isogarcinol accu-
mulated in the ethanol phase while anthocyanin and
hydroxycitrate built up in the salt-rich phase.[24] Gold
nanoparticles (AuNPs), prepared from G. indica fruit
rind extract, showed distinct catalytic activities such as
a reduction of toxic 4-nitrophenol to 4-aminophenol
when combined with NaBH4.
[25]
Distinct progress has also been achieved in the
field of the total synthesis of garcinol and isogarcinol.
Socolsky and Plietker described a concise total syn-
thesis of racemic garcinol and isogarcinol in 13 steps
starting from acetylacetone, which was α-prenylated
and reacted with formaldehyde via deacetylating
aldol-type condensation to give enone 1 (Scheme 1).
The latter was submitted to a domino Michael
addition–Knoevenagel condensation with dimethyl
1,3-acetonedicarboxylate to afford the cyclohexanone
hub of intermediates 2 and 3. Allylation of the keto
ester 3 with 4-acetoxyprenyl chloride gave trans-
selectively 4, which was β-methylated and O-alloc
protected to furnish enol allyl carbonates 5a and 5b.
Both regioisomers 5 underwent a carboxylative, dia-
stereoselective, Pd-catalyzed Tsuji–Trost allylation
yielding the same cyclohexanone 6. Its subsequent Pd-
catalyzed allyl-allyl cross-coupling with allylpinacolbor-
ane afforded exclusively the 1,5-dienyl derivative 7,
which was submitted to a Dieckmann condensation
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leaving bicyclo[3.3.1]nonatrione 8. Its cross-metathesis
with amylene to introduce the prenyl residues,
followed by benzoylation and deprotection finally
yielded the natural product garcinol.[26]
3. An Update on The Activities of Garcinol and
Isogarcinol against Tumor Models
The significant activity of garcinol and isogarcinol
against various tumor models is largely attributed to
the inhibition of histone acetyl transferases (HATs), NF-
κB signaling, and STAT-signaling. Meanwhile, new
promising results were disclosed (Table 1).
Lung cancer is one of the most lethal cancers and
leads annually to ca. 1.2 million deaths worldwide.[27]
Non-small cell lung cancer cells were sensitized to
cisplatin and erlotinib treatment by garcinol. This
effect was mediated by miRNAs and garcinol was able
to upregulate EMT-modulating miRNAs such as let-7c
and miR-200b.[28] Lung cancer stem cells (LCSCs) were
also targeted by garcinol and repression of the Wnt/β-
catenin/STAT3 signaling pathway by garcinol treat-
ment suppressed the ability of NSCLC cells to form
Scheme 1. Total synthesis of garcinol published by Socolsky and Plietker.[26]
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spheres and reduced the tumor growth in the H441
LCSC mouse xenograft model.[29] In addition, garcinol
activated DDIT3 (DNA damage-inducible transcript 3)
and suppressed the cancer stem cell marker ALDH1 A1
(aldehyde dehydrogenase 1 family member A1) in
A549 NSCLC cells.[30]
Colorectal cancer (CRC) also belongs to the most
lethal cancer diseases worldwide.[31] The emergence of
CRC is closely connected with genetic factors (ca. 25%
of CRC appears in people with close relatives suffering
from CRC), as well as obesity and dietary factors.[32]
HT-29 CRC cells treated with garcinol showed in-
creased apoptosis rates, reduced cell growth, and a
less pronounced tendency to angiogenesis and inva-
sion due to downregulation of mPGES1, HIF-1α, VEGF
and MMP expression.[33] In HCT-116 CRC cells, the HAT
inhibitory activity of garcinol reduced 8-oxoG damage
repair by suppression of base excision repair (BER).[34]
Breast cancer is the most prevalent cancer type of
women.[35] Resistance to chemotherapy is a big
problem. Garcinol was able to sensitize breast tumors
to treatment with taxol in vitro and in vivo (orthotopic
4T1 mammary carcinoma). Synergistic tumor growth
inhibition and anti-metastatic activity were observed
Table 1. Recently discovered antitumor effects of garcinol and isogarcinol.
Cancer type Effects Mechanisms In vivo activity
Lung cancer Sensitization to cisplatin and erlotinib
(garcinol),[28] suppression of cancer
stem cells (garcinol),[29,30] increased
TRAIL-based apoptosis (garcinol)[54]
Upregulation of let-7c and miR-200c
(garcinol),[28] suppression of Wnt/β-cat-
enin/STAT3 and ALDH1 A1 (garcinol),[29]
activation of DDIT3, induction of DR5
(garcinol),[30] suppression of c-FLIP
(garcinol)[54]
Inhibition of H441 LCSC mouse
xenograft tumor growth
(garcinol)[29]
Colorectal
cancer
Increased apoptosis and cell growth
inhibition (garcinol),[33] inhibition of
angiogenesis and invasion (garcinol),[33]
inhibition of DNA repair (garcinol)[34]
Suppression of mPGES1, HIF-1α, VEGF,
MMP (garcinol),[33] inhibition of base
excision repair via HAT inhibition
(garcinol)[34]
–
Breast cancer Sensitization to taxol (garcinol),[36] in-
creased apoptosis (garcinol)[13]
Suppression of caspase-3/iPLA2 and NF-
κB/Twist1 signaling (garcinol),[36] p53
dependent induction of Bax
(garcinol),[13] suppression of Bcl-XL
(garcinol),[13] proteasome-based degra-
dation of ADA3 (garcinol)[55]
Sensitization to taxol in ortho-
topic 4T1 mammary carcinoma
(garcinol)[36]
Prostate can-
cer
Increased apoptosis, inhibition of au-
tophagy (garcinol)[38]
Induction of Bax, suppression of Bcl-2
and mTOR (garcinol)[38]
Inhibition of PC-3 mouse xeno-
graft tumor growth
(garcinol)[38]
Pancreatic
cancer
Suppression of cancer stem cell charac-
ter (garcinol),[40] tumor growth inhibi-
tion (garcinol)[41]
Suppression of Mcl-1, EZH2, ABCG2,
Gli-1, and Notch-1, induction of miR-
200c (garcinol)[40]
Inhibition of tumor growth in
KPC mice: K-ras and p53 condi-
tional mutant mice
(garcinol)[41]
Oral squa-
mous cell car-
cinoma
Inhibition of tumor cell growth, induc-
tion of apoptosis, inhibition of angio-
genesis and colony formation
(garcinol)[43]
Inhibition of NF-κB and COX-2, suppres-
sion of VEGF (garcinol)[43]
–
Cervical can-
cer
Inhibition of tumor cell growth
(garcinol),[48,53] suppression of tumori-
genesis (garcinol),[48] sensitization to
radiotherapy (garcinol)[49]
Activation of PI3 K/AKT signaling
(garcinol),[48] suppression of HIF-1α
(garcinol)[49]
Induction of T-cadherin in vivo
(garcinol)[48]
Miscellaneous
cancers
Tumor cell growth inhibition [gallblad-
der carcinoma (garcinol),[50] neuroblas-
toma (garcinol),[51] melanoma (GAR-
NPs),[53] hepatoma (GAR-NPs),[53] leuke-
mia (isogarcinol)],[19] synergism with
STAT5-SH2 domain inhibitor AC-4-130
(leukemia, garcinol),[52] induction of
apoptosis and G2/M arrest (leukemia,
isogarcinol),[19] induction of autophagy
(osteosarcoma, garcinol)[56]
Suppression MMP2 and MMP9 (gall-
bladder carcinoma) (garcinol),[50] syner-
gism with STAT5 inhibition via HAT
inhibition (leukemia, garcinol),[52] in-
creased TRAIL-based apoptosis by in-
duction of DR5 and suppression of c-
FLIP (hepatoma, renal cancer,
garcinol),[54] LC-3 shift (osteosarcoma,
garcinol)[56]
Moderate accumulation of gar-
cinol nanoparticles in tumors
of B16-F10 tumor bearing mice
(GAR-NPs)[53]
Chem. Biodiversity 2019, 16, e1900366
www.cb.wiley.com (4 of 13) e1900366 © 2019 The Authors. Chemistry & Biodiversity Published by Wiley-VHCA AG
for this promising drug combination at low doses
(1 mg/ kg garcinol orally three times per week+5 mg/
kg taxol i. p. once per week) attributable to the
downregulation of caspase-3/iPLA2 and NF-κB/Twist1
signaling.[36] The chloroform extract of G. morella rich
in bioactive garcinol exhibited distinct growth inhib-
itory effects against three breast cancer cell lines
(MCF-7, MDA-MB-231, SKBR3). MCF-7 cells treated with
the G. morella chloroform extract revealed increased
apoptosis levels by p53 dependent induction of Bax
and suppression of Bcl-XL.
[13]
In the Western world prostate cancer is the second
most frequent cause of cancer-related death after lung
carcinoma.[37] In PC-3 prostate carcinoma cells, garci-
nol induced apoptosis by induction of Bax and
suppression of Bcl-2 as well as by inhibition of
autophagy via activating phosphorylation of mTOR.
Garcinol (50 mg/kg five times per week for 40–
50 days, i. p. or orally) also inhibited tumor growth of
PC-3 mouse xenografts by 80%.[38]
Individuals diagnosed with pancreatic cancer (PC)
still face a poor prognosis.[39] The high incidence of
resistance and metastasis of pancreatic cancer was
correlated to the presence of cancer stem-like cells
that are also called side population (SP) cells. Garcinol
suppressed the stem cell character of Panc-1 SP cells
by inhibition of crucial SP-related factors such as Mcl-
1, EZH2, ABCG2, Gli-1, and Notch-1. In addition,
upregulation of the tumor suppressor microRNA miR-
200c (target: Notch-1) was observed upon garcinol
treatment.[40] In transgenic PC mice (KPC mice: K-ras
and p53 conditional mutant mice), garcinol and the
combination of a garcinol diet with injected gemcita-
bine inhibited tumor growth.[41]
With more than 300,000 people suffering from oral
squamous cell carcinoma (OSCC) every year all over
the world, this malignancy is the sixth most common
tumor disease and many cases go on developing
countries.[42] Garcinol inhibited the tumor cell growth
of the OSCC cell lines SCC-4, SCC-9 and SCC-25 in vitro
(IC50=5  15 μM), induced apoptosis in these cancer
cells, blocked angiogenesis and reduced significantly
the number of formed colonies by SCC-4 and SCC-9
cells. Inhibition of NF-κB and of COX-2 as well as
suppression of VEGF were identified as modes of
action of garcinol in these OSCC cells.[43] The chemical
modification of garcinol allowed insights into the
importance of functional groups of this compound
concerning activity against tumor models. For in-
stance, the 13,14-dihydroxy groups proved essential
for the activity of garcinol because their methyl ethers
exhibited weaker activity against SCC15 OSCC cells.[44]
The total synthesis and testing of an 8-methyl garcinol
derivative showed the high importance of the 8-prenyl
group of natural garcinol for activity against SCC15
cells.[45] In contrast, the synthetic 8-allyl garcinol
derivative displayed a strong growth inhibition of oral
cancer cells.[46]
Cervical carcinoma (CC) is the cause of death of
300,000 women globally every year and patients with
metastases and suffering from relapse have a poor
prognosis.[47] Garcinol showed activity against CC
models. Tumorigenesis of CC was correlated with T-
cadherin expression and garcinol induced T-cadherin
in vitro and in vivo via activation of PI3 K/AKT signaling
in CC.[48] Radiation therapy is customarily applied for
CC patients and, thus, it is interesting to note that
garcinol increased the sensitivity of oxygen-deficient
HeLa CC cells to radiation by suppression of HIF-1α.[49]
In addition, the effects of garcinol and isogarcinol
were studied in various other cancers. Garcinol
inhibited gallbladder carcinoma (GBC) cell growth and
cell invasion by suppression of the matrix metal-
loproteinases MMP2 and MMP9. Both STAT3 and Akt
were downregulated by garcinol in GBC-SD cells.[50]
Garcinol and the chloroform extract of G. morella
inhibited the growth of the childhood tumor and
neuroblastoma cell line SH-SY5Y (IC50=6.3 μM for
garcinol).[51] Both garcinol and isogarcinol displayed
activities against leukemia models. The STAT5-SH2
domain inhibitor AC-4-130 showed strongly synergistic
effects against acute myeloid leukemia (AML) cells
MV4-11 and MOLM-13 in combination with the HAT
inhibitor garcinol probably because acetylation of
STAT5 by the HATs p300 and PCAF is of importance
for the regulation of STAT5 phosphorylation/
dimerisation.[52] Isogarcinol isolated from G. ovalifolia
roots exhibited distinct activity against HL-60 promye-
locytic leukemia cells (IC50=4 μg/mL) and induced G2/
M arrest as well as apoptosis via mitochondrial
damage in these leukemia cells.[19] While garcinol is
only poorly soluble in water, PLGA nanoparticles
modified with vitamin E as carriers of garcinol (GAR-
NPs) revealed significant growth inhibitory activities
against B16-F10 melanoma, HepG2 hepatocellular
carcinoma, and KB cervical carcinoma cells. The GAR-
NPs showed improved uptake rates, time-dependent
accumulation in B16-F10 tumor bearing mice as well
as apoptosis induction.[53]
New discoveries concerning mechanisms of action
of garcinol and isogarcinol in tumor models were
disclosed. In hepatoma (SK-Hep1), lung (A549) and
renal carcinoma cells (Caki, ACHN, A498) garcinol
increased TRAIL-based apoptosis by induction of DR5
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and suppression of c-FLIP.[54] The HAT inhibitor
garcinol also led to proteasome-based degradation of
the factor ADA3 (alteration/deficiency in activation 3)
in immortalized 76 N-TERT cells (human mammary
epithelial cells) by inhibition of stabilizing ADA3
acetylation via p300/PCAF inactivation.[55] In this way,
garcinol may show synergistic effects in combination
with EGFR inhibitors. In U2OS osteosarcoma cells
garcinol induced autophagy and a correlated LC3-shift
by inhibition of EP300 (E1 A-binding protein p300).[56]
The HAT BRD4 (bromodomain protein 4) enhanced the
transcription of target genes such as MYC, FOS and
AURKB (Aurora kinase B) but BRD4 was efficiently
inhibited by garcinol while another pan-inhibitor
(curcumin) displayed no BRD4 inhibitory effects.[57]
Hence, BRD4 inhibition can contribute to the activity
of garcinol. Garcinol was described as a time- and
detergent-dependent inhibitor of lysine acetyltransfer-
ases (KATs, a more specific name for HATs). High
Triton-X-100 concentrations (0.05%) reduced the KAT-
inhibitory activity of garcinol for p300 and GCN5 KATs
when compared with experiments using low Triton-X-
100 concentrations (0.01%), which is of great impor-
tance for future biological tests with garcinol in order
to obtain reasonable results.[58] Because of these
findings an aggregation-based mode of KAT inhibition
was suggested for garcinol. Based on the lead
compound garcinol, a synthetic and non-competitive,
selective and reversible inhibitor (EML245) of the KAT3
enzymes p300 (Ic50=2.9 μM) and CBP (IC50=1.1 μM)
was obtained. EML245 showed significant cell perme-
ation and reduced lysine H4 K5 and H3 K9 acetylation
in U937 leukemia cells leading to G0/G1 arrest and
formation of hypodiploid nuclei.[59]
4. An Update on The Activities of Garcinol
against Viruses, Bacteria, Yeasts, and
Protozoal Parasites
Garcinol has shown promising activity against causing
agents and consequences of various infectious dis-
eases. Table 2 summarizes a few of the more interest-
ing findings.
As early as 2007, the suppression of viral tran-
scription by HIV was documented for isogarcinol
derivatives as well as their p300 inhibitory activity.[60]
Recently, a similar mode of action against the
influenza virus was reported of garcinol. Garcinol
inhibited both PCAF (p300/CBP-associated factor) and
GCN5 in influenza A leading to a reduced acetylation
of the viral nucleoprotein and to the regulation of the
viral polymerase function. Interestingly, both HATs
target different lysines of the nucleoprotein: while
PCAF acetylate Lys-31, GCN5 acetylates Lys 90. Both
lysines regulate opposite effects: deacetylated Lys-31
(by suppression of PCAF) enhanced viral polymerase
activities while deacetylated Lys-90 (by suppression of
GCN5) decreased the viral polymerase function.[61]
The lethal toxin (LT) of the Gram-positive bacterium
Bacillus anthracis induces actin stress fiber formation
in infected cells by suppression of HDAC expression
and, thus, this process is controlled by histone
acetylation. In contrast to LT, the HAT inhibitor
garcinol reduced stress fiber formation in LT-treated
HUVEC cells and so might act as an antidote for LT
intoxication.[62]
The activity of garcinol against cells of the patho-
genic fungus Candida albicans was studied as well.
Garcinol and xanthochymol induced apoptosis in C.
albicans hyphae and inhibited biofilm production by
this fungus.[15]
The viability of Toxoplasma gondii, which is a
protozoal parasite causing toxoplasmosis, is regulated
by lysine acetylation. The GCN5 family KAT TgGCN5b
of T. gondii is crucial for replication of the T. gondii
tachyzoites. Garcinol treatment led to decreased levels
of acetylated histone H3 of TgGCN5b and to an
inhibition of replication (IC50=1.7 μM). Similar replica-
tion inhibitory effects were observed for the malaria
parasite Plasmodium falciparum (IC50=1.69 μM for
chloroquine-sensitive HB3 strains, and IC50=2.05 μM
for chloroquine-resistant Dd2 strains; inhibition of
erythrocytic asexual replication).[63]
Table 2. Recently discovered effects of garcinol on infection-
causing agents.
Infection Effects Mechanisms
Influenza
A[61]
Regulation of viral polymer-
ase function
Inhibition of PCAF
and GCN5
Bacillus
anthracis[62]
Antidote for LT intoxication Reduction of
stress-fiber forma-
tion
Candida
albicans[15]
Induction of apoptosis, in-
hibition of biofilm formation
–
Toxoplasma
gondii[63]
Inhibition of replication Inhibition of
TgGCN5b
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5. New Effects on Inflammation Processes and
Neurodegenerative Diseases
The antioxidant and anti-inflammatory properties of
garcinol and isogarcinol are well described (Table 3).[10]
Only recently, isogarcinol was reported to have
significant antioxidant effects rescuing human cells
from oxidative stress while the genotoxicity of iso-
garcinol was negligible.[64] Topically applied garcinol
efficiently blocked skin inflammation and tumorigene-
sis induced by 12-O-tetradecanoylphorbol 13-acetate
in mice by suppression of NF-κB, ERK, JNK, p38 MAPK,
PI3 K and Akt.[65] Intimal hyperplasia is based on
vascular inflammation and NF-kB activation and the
HAT PCAF promoted NF-κB-regulated inflammation.
Garcinol suppressed CCL2 and TNF-α expression in
leukocytes and vascular smooth muscle cells and
Table 3. Recently discovered effects of garcinol and isogarcinol on inflammation and neurodegenerative diseases.
Disease Effects Mechanisms
Skin inflammation Inhibition of 12-O-tetradecanoylphorbol induced
inflammation process and tumorigenesis in vitro
and in vivo[65]
Suppression of NF-κB, ERK, JNK, p38 MAPK, PI3 K,
and Akt[65]
Intimal hyperplasia Suppression of leukocyte and vascular smooth
muscle cell inflammation process in vitro, reduced
arterial adherence and infiltration by leukocytes
and macrophages in vivo[66]
Suppression of CCL2 and TNF-α[66]
LPS-induced inflamma-
tion
Increase of LPS-induced inflammation process in -
vitro and in vivo[67]
Increased expression of TNF-α and IL-6[67]
Collagen-induced arthri-
tis (CIA)
Suppression of CIA and ear edema, reduced bone
and cartilage damage and low concentrations of
inflammatory cytokines in vivo[68]
Suppression of NF-κB, iNOS, COX-2, NFAT and IL-
2[68]
Systemic lupus erythe-
matosus (SLE) disease
Protection of kidneys in vivo, reduced renal histo-
pathology and proteinuria, normalized serum bio-
chemical indicator[69]
–
Psoriasis Amendment of skin lesions induced by imiquimod,
less toxic to liver and kidneys than cyclosporine A
in vivo[70]
Suppression of IL-23/Th17 axis genes[70]
Macrophages Beneficial effects on macrophages and peritoneal
macrophages, reduced excretion of lysosomal
enzymes in vivo[71]
Suppression of collagenase, elastase and hyalur-
onidase excretion[71]
Liver inflammation and
acute liver failure
Prolonged survival of mice with acute liver
failure[73]
Suppression of histone acetylation[73]
Endometriosis Suppression of fibrosis in Klf11  /  animals[74] Restoration of transcription factor KLF11 function,
suppression of scar-tissue collagen (COL1 A1/
Col1a1)[74]
Obesity-related inflam-
mation
Inhibition of high fat diet (HFD)-induced obesity in
vivo[75]
Increased levels of intestinal commensal bacteria
Akkermansia, suppression of glutamate pyruvate
transaminase, cholesterol and triacylglycerol[75]
Diabetes Normalization of diabetic parameters in vivo[77]
Osteolysis Suppression of osteoclastogenesis in vitro and in
vivo[79]
Suppression of PI3 K/Akt, MAPK and NF-κB
signaling[79]
Multiple sclerosis, exper-
imental autoimmune en-
cephalomyelitis
Reduced intracranial lesions and demyelination of
the spinal cord in vivo[80]
Targeting of JAK/STAT signaling pathway[80]
Neuropathic pain Prolonged thermal withdrawal latency[81] Suppression of acetyl-p65[81]
Neuroinflammation of
microglia
Suppression of inflammation factors in vitro and in
vivo[82]
downregulation of NF-κB signaling, reduced ex-
pression of COX-2/PGE2, iNOS and interleukins (IL-
1b, IL-6)[82]
Parkinson’s disease Neuroprotective effects,[83] reduction of dopamine
side-effects/dyskinesia[84,85]
MAO  B inhibition,[83] inhibition of catechol-O-
methyltransferase[85]
Epilepsy Decrease of mortality and of seizure scores in
vivo[86]
Suppression of BDNF and TrkB and upregulation
of GABAA and GAD65
[86]
Cocaine abuse Support of drug abstinence[87,88] Inhibition of reinstatement by reconsolidation-
based modes[85,88]
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reduced arterial adherence and infiltration by leuko-
cytes and macrophages in vivo when administered in a
Pluronic gel enabling a slow garcinol drug release.[66]
In contrast to these and other previous findings about
the considerable anti-inflammatory activities of garci-
nol, a newer study described the enhancement of
lipopolysaccharide(LPS)-induced inflammation by in-
traperitoneally administered garcinol (injection of
10 mg/kg in DMSO) both in vitro and in vivo.[6,67] The
expression of TNF-α and IL-6 was markedly increased
by garcinol in this case, which was correlated with
reduced acetylation of NF-κB. Hence, more research is
necessary into the positive and negative effects of
garcinol on various forms of inflammation processes.
Orally administered isogarcinol (100 mg/kg)
showed significant activity against collagen-induced
arthritis (CIA) and xylene-induced ear edema in mice.
Reduced bone and cartilage damage as well as low
concentrations of inflammatory cytokines were ob-
served upon isogarcinol treatment of CIA mice.
Suppression of the expression of NF-κB, iNOS, COX-2,
NFAT and IL-2 was observed after treatment with
isogarcinol from in vitro experiments.[68] The same
group investigated the activity of isogarcinol against
systemic lupus erythematosus (SLE). Mice with chronic
graft-versus-host disease (cGVHD, an SLE in vivo mod-
el) were treated with isogarcinol (60 mg/kg) leading to
reduced renal histopathology and proteinuria as well
as normalized serum biochemical indicator.[69] Isogarci-
nol (100 mg/kg, orally) also amended skin lesions
(similar to psoriasis) induced by exposure to imiqui-
mod in mice. Suppression of IL-23/Th17 axis genes of
isogarcinol-treated mice was observed while isogarci-
nol was less toxic to liver and kidneys than cyclo-
sporine A.[70]
A diet of garcinol (5 mg/kg per day) in groundnut
oil was given to male Wistar rats in order to investigate
any drug effects on peritoneal macrophages of
garcinol-fed rats. It showed positive effects and
reduced excretion of lysosomal enzymes such as
collagenase, elastase and hyaluronidase.[71] In addition,
isogarcinol exerted its immune modulatory effects by
direct binding and inhibition of calcineurin.[72] Histone
acetylation was also correlated with liver inflammation
and acute liver failure in mice and treatment with
garcinol (20 mg/kg/day, i. p.) suppressed histone acety-
lation and prolonged survival of mice suffering from
acute liver failure.[73] In endometriosis models, garcinol
(0.2 μg/g/day, i. p.) could replace the function of the
transcription factor KLF11, a repressor of scar-tissue
collagen (COL1 A1/Col1a1), leading to fibrosis reversal
in Klf11  /  animals.[74] Obesity-related inflammation
was regulated by garcinol via increase of levels of
intestinal commensal bacteria Akkermansia. Garcinol
blocked the formation of high fat diet (HFD)-induced
obesity and suppressed glutamate pyruvate trans-
aminase, cholesterol and triacylglycerol in the plasma
of animals fed with garcinol.[75] Pretreatment of leptin-
stimulated cells with garcinol (1 μM) also inhibited
leptin-associated cPLA2 expression via inhibition of
p300 HAT.[76] In addition, garcinol displayed beneficial
effects on diabetic Wistar rats and oral application of
garcinol (10 mg/kg and 20 mg/kg) normalized diabetic
parameters in the rats similar to the antidiabetic drug
glibenclamide.[77] Osteolysis is often based on acti-
vated osteoclasts which are bone-resorbing osteoim-
mune cells.[78] Osteoclastogenesis relies on RANKL
(receptor activator of NF-κB) and treatment of BMM
cells (bone marrow monocytes) with garcinol in vitro
and of C57BL/6 mice in vivo (mouse calvarial osteolysis
model. sub-cutaneous injection of 5 mg/kg in) sup-
pressed osteoclastogenesis by downregulation of
PI3 K/Akt, MAPK and NF-κB signaling.[79]
Effects of garcinol and isogarcinol on various neural
inflammation and neural degenerative disease models
were disclosed. Experimental autoimmune encephalo-
myelitis (EAE) is a preclinical murine model for the
investigation of multiple sclerosis (MS). EAE mice
treated with isogarcinol (100 mg/kg/day, orally)
showed lower degrees of intracranial lesions and
demyelination of the spinal cord due to drug interfer-
ence with the JAK/STAT signaling pathway.[80] Thus,
isogarcinol can be a little toxic alternative to currently
applied drugs for the treatment of MS. Intrathecal
injections of garcinol in rats (L5 spinal nerve ligation/
SNL model) prolonged thermal withdrawal latency
(TWL) and, thus, reduced neuropathic pain likely via
suppression of acetyl-p65.[81] Neuroinflammation of
microglia was suppressed by treatment with garcinol
and downregulation of NF-κB signaling. Garcinol also
reduced the expression of COX-2/PGE2, iNOS and
interleukins (IL-1b, IL-6) in the SNL rat spinal cord.[82]
Monoamine oxidase-B (MAO  B) metabolizes dopa-
mine and, thus, represents a suitable target for the
treatment of Parkinson’s disease (PD) based on
dopamine depletion in certain parts of the brain.
Garcinol exhibited a distinct MAO  B inhibition similar
to known MAO  B inhibitors and together with its
neuroprotective effects, this compound appears partic-
ularly promising for the treatment of PD.[83] Garcinol
also reduced the side-effects of dopamine replace-
ment therapy by L-DOPA. Dyskinesia induced by L-
DOPA in 6-hydroxydopamine (6-OHDA)-lesioned mice
was reduced by co-treatment with garcinol (5 mg/kg,
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orally).[84] Garcinol also inhibited catechol-O-meth-
yltransferase leading to an increased L-DOPA bioavail-
ability and it reduced hyperhomocysteinemia associ-
ated with L-DOPA treatment. This indicates the great
potential of garcinol for the treatment of PD in
combination with L-DOPA.[85] It was observed that
garcinol-pretreatment (50, 100 or 200 mg/kg, i.p.) of
mice with pentylenetetrazole (PTZ)-induced epilepsy
led to a marked decrease of mortality and of seizure
scores. In addition, the memory and cognition of these
garcinol-treated mice improved distinctly. Suppression
of BDNF and TrkB by garcinol as well as garcinol-
induced upregulation of GABAA and GAD65 were
identified as anti-epileptic modes of action of
garcinol.[86] Garcinol (10 mg/kg, i. p.) also showed
beneficial effects in rats exposed to cocaine and it
inhibited reinstatement by reconsolidation-based
modes following cocaine reactivation.[87,88] Reactivated
memories were affected by garcinol which displayed
long-lasting effects and, thus, garcinol can support
drug abstinence and be a suitable therapy for
psychopathologies such as drug addiction. Indeed,
memory processes in honeybees strongly depend on
HAT activity and histone H3 acetylation by treatment
with garcinol or C646.[89]
6. Miscellaneous Activities and Applications
The establishment of garcinol as a proper drug is in
progress. The Indian company Sami Labs Ltd. isolated
garcinol by extraction of dried kokum plum rinds with
hexane followed by column chromatography and
crystallization from hexane and this company has
standardized garcinol (40% garcinol in microcrystalline
cellulose) and evaluated the toxicity of 40% garcinol
in Wistar rats. In fact, 40% garcinol exhibited a low
toxicity and no signs of any side-effects at doses of up
to 100 mg/kg/day (orally) after weeks and months.[90]
There are also successful efforts to produce fruit
wines from kokum and the fermentation of a mixture
of kokum juice with banana juice generated an
excellent wine which has the potential to conquer the
exotic wine market in the future.[91]
The preparation of effective sunscreens with kokum
extract is also possible. The ethyl acetate extract of
kokum, which is rich in garcinol, when washed with
water in order to remove hydroxycitric acid, showed
significant UV-radiation protective effects. A cosmetic
cream containing 5% of the extract revealed a sun
protection factor of 3.43 with boot star rating 5.[92]
Garcinol isolated from the fruits of the Thai plant
Garcinia dulcis also showed vasorelaxant activity. It
might be a suitable drug for the treatment of hyper-
tension due to its antioxidant activity. Injection of
hypertensive 2 K1 C (2-kidneys-1-clip) rats with low
doses of garcinol (0.1 mg/kg, i. v.) led to hypotensive
effects and reduced arterial blood pressure, heart rate,
plasma malondialdehyde values, and eNOS
expression.[93]
Eryptosis is a programmed cell death process to
eliminate defective erythrocytes (prior to nephrotoxic
hemolysis) analogously to apoptosis of damaged cells
with nuclei.[94] In particular, eryptosis has been identi-
fied as a mechanism to fight infection with Plasmo-
dium (malaria), for example, in sickle-cell trait, in order
to eliminate infected erythrocytes and the parasites
therein. Human erythrocytes treated with garcinol
(5 μM) underwent eryptosis according to increased
annexin-V binding, increased ROS formation and
reduced ATP level of the cytosol.[95] Thus, garcinol has
the potential to fight Plasmodium-caused diseases via
this peculiar mode of action.
7. Conclusions
The chemistry and biology of garcinol and isogarcinol
are active and prospering fields of research. The total
synthesis of garcinol by Socolsky and Plietker repre-
sents a chemical highlight of the past years and
enables the fine-tuning of the garcinol molecule
concerning improved biological activities by prepara-
tion of synthetic garcinol derivatives. The identification
of new HATs as targets of garcinol or isogarcinol
broadens the scope of application of these natural
products including activities against viral and parasitic
models. In addition, their distinct activities against
cancer stem-like cells warrant studies against further
tumor models. One report has appeared that de-
scribed a promoting effect on LPS-induced inflamma-
tion processes. This is in stark contrast to many other
publications which describe garcinol or isogarcinol as
potent agents against various inflammation processes.
Future studies will show if this is just a solitary case. It
is noteworthy that garcinol was also found active
against models of various neurological diseases such
as EAE, Parkinson disease, epilepsy or drug addiction.
These discoveries underline once more the potential
of garcinol and isogarcinol as valuable drug candi-
dates.
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